Moberg Pharma AB (Formerly known as Moberg Derma): MOB-015 Data To Be Presented At The 73rd Annual Meeting Of The American Academy of Dermatology

STOCKHOLM--(BUSINESS WIRE)--Regulatory News:

Moberg Pharma AB (STO:MOB) today announced that Professor Jan Faergemann, Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden and Principal Investigator of the phase-II clinical trial on the Company’s product candidate for onychomycosis MOB-015, will present at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) on March 22, 2015 in San Francisco, CA

Help employers find you! Check out all the jobs and post your resume.